Form D · Biotechnology

Morphic Holding, Inc.

Waltham, MA · CIK 0001679363

Offering snapshot reported Mar 1, 2023 · SEC filing

Reported sold
$100M
Offering amount: $100M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 15, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 1, 2023Initial$99,999,755No comparison4SEC filing
Oct 1, 2018Initial$79,999,990No comparison13SEC filing
Jul 13, 2016Initial$20,599,999No comparison12SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-474629

Source: Form D, filed Mar 1, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Norbert Bischofberger Director
Kevin Bitterman Director
Gustav Christensen Director
Barbara Dalton Director
William De Vaul Executive
Martin Edwards Director
Ramy Farid Director
Robert E. Farrell Executive
Vikas Goyal Director
Susannah Gray Director
Nilesh Kumar Director
Alexey A. Lugovskoy Executive
Nisha Nanda Director
Amir Nashat Director
Bruce Rogers Executive
Marc Schegerin Executive
Joseph P. Slattery Director
Timothy A. Springer Director
Otello Stampacchia Director
Praveen P. Tipirneni Director, Executive
Praveen Tiprirneni Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
35 Gatehouse Drive A2
Waltham, MA, 02451